Human Growth Hormone vs Hexarelin.

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS), structurally derived from the GHRP-6 family of growth hormone-releasing peptides. It is an investigational compound that was studied in the 1990s and 2000s as a potential agent for probing and stimulating growth hormone secretion and, separately, for direct effects on the heart. It is not an approved drug.

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

Hexarelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same pituitary/hypothalamic receptor activated by the natural hormone ghrelin. Receptor binding engages Gq/11-phospholipase C signaling, mobilizing intracellular calcium in pituitary somatotrophs and triggering pulsatile growth hormone release; this pathway is distinct from and synergistic with GHRH, and also opposes somatostatin tone. Hexarelin additionally binds CD36, a scavenger receptor expressed in cardiac and vascular tissue, which is the proposed basis for GH-independent cardiovascular effects observed in animal models. Because it is a non-selective secretagogue, it also stimulates ACTH/cortisol and prolactin release to a greater degree than more selective agents.

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

Human data exist but are limited to small, short-term, acute physiology studies rather than outcome trials. Acute intravenous hexarelin reliably raised serum growth hormone in healthy volunteers and was compared head-to-head with GH in a controlled human study (Imbimbo/Ghigo group, J Endocrinol Invest 1999, PMID 10342360). Separate small studies reported short-lasting increases in left ventricular ejection fraction and cardiac output in normal subjects, GH-deficient patients, and dilated-cardiomyopathy patients, effects that appeared GH-independent (Bisi/Broglio et al., Endocrine 2001, PMID 11322491). A chronic-administration study found that GH responses desensitized over weeks and characterized effects on the pituitary-adrenal axis and prolactin (Clin Endocrinol 1999, PMID 10341859). Most cardioprotection evidence (CD36-mediated ischemia/reperfusion protection, IL-1 signaling) is preclinical and rodent-based (e.g., Int Heart J 2017, PMID 28321024; review J Geriatr Cardiol 2014, PMID 25278975); none of this advanced to a successful human cardiac outcome trial, and clinical development was discontinued.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

Documented effects in human studies include hexarelin's lack of GH selectivity: it raises cortisol, ACTH, and prolactin alongside growth hormone, so it does not produce a clean GH signal. A well-described limitation is rapid tachyphylaxis/desensitization, with attenuated GH responses on repeated or continuous dosing demonstrated both in vitro (second-messenger level) and over weeks of human administration. Long-term safety in humans is essentially unknown because no large or extended trials were completed; chronic GHS-driven IGF-1 elevation raises theoretical concerns common to this class (fluid retention, insulin sensitivity changes, and the general caution that growth-promoting signaling could be undesirable in the setting of malignancy), but these are not established for hexarelin specifically. There is no established safety profile for non-clinical/self-administered use.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

Hexarelin is investigational and has never received FDA or EMA marketing approval; its clinical development was discontinued. It is prohibited in sport at all times by WADA as a growth hormone secretagogue / GH-releasing peptide under category S2 of the Prohibited List, and it is generally sold only as a research-use-only chemical.